Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

INTRANASAL APPLICATION OF LACTOCOCCUS LACTIS W 136 BACTERIA EARLY IN SARS-Cov-2 INFECTION MAY HAVE A BENEFICIAL IMMUNOMODULATORY EFFECT: A PROOF-OF-CONCEPT STUDY

Leandra Mfuna Endam, Cécile Tremblay, Ali Filali, View ORCID ProfileMartin Yvon Desrosiers
doi: https://doi.org/10.1101/2021.04.18.21255699
Leandra Mfuna Endam
1Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cécile Tremblay
1Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM)
2Centre Hospitalier de l’Université de Montréal (CHUM)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Filali
1Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM)
2Centre Hospitalier de l’Université de Montréal (CHUM)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Yvon Desrosiers
1Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM)
2Centre Hospitalier de l’Université de Montréal (CHUM)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martin Yvon Desrosiers
  • For correspondence: desrosiers_martin@hotmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Justification Stimulation of early innate anti-viral responses during the early phase of SARS-COV-2 infection oxygen may improve evolution of illness and late pulmonary complications. This may be possible using a TLR agonist such as a probiotic bacterium possessing desirable immunomodulatory properties.

Method We performed a non-contact, open-label, prospective randomized clinical trial comparing intranasally applied Lactococcus lactis W136 with saline irrigation alone in patients within 96 hours of diagnosis of SARS-COV-2 infection not requiring supplemental oxygen.

Results Twenty-three of a planned forty participants aged 18-59 without comorbidities were recruited. Irrigation with intranasal L lactis W136 twice-daily for fourteen days of was associated with a nasal response characterised by increase in the symptom of Facial and Throat pain/discomfort, and with a lesser severity in symptoms of i) Fatigue ii) Olfactory dysfunction and iii) Breathlessness. Safety and tolerability were good, with no acute infections or severe deteriorations.

Interpretation Facial and throat pain may correspond to postulated mechanism of action corresponding to activation of innate defences with antiviral effects and may explain the potentially protective effects seen. Intranasal L lactis W136 irrigations may thus represent a potentially inexpensive, safe, and easily scalable non-antigen based therapeutic for the continuing global SARS-COV-2 pandemic.

Data availability statement Data is available on request from the senior author, Dr Desrosiers: martin-yvon.desrosiers.med@ssss.gouv.qc.ca

Funding This work was supported with internal funds from the Desrosiers laboratory at the Centre de Recherche du Centre Hospitaller de l’Université de Montreal (CRCHUM).

Competing Interests Dr Desrosiers holds equity in Probionase Therapies inc., Which commercialises Lactococcus lactis W136 for chronic rhinosinusitis.

Competing Interest Statement

Dr Desrosiers has an equity stake in Probionase Therapies, Inc., which commercializes Lactococcus lactis W136 for management of symptoms of chronic sinusitis with and without nasal polyposis.

Clinical Trial

ClinicalTrials.gov. identifier: NCT04458519

Funding Statement

This work was supported with internal funds from the Desrosiers laboratory at the Centre de Recherche du Centre Hospitaller Universite de Montreal (CRCHUM).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Approval was obtained from the CHUM Institutional Review Board and Ethics committee (Registration No. 20.012) prior to trial performance. Given the innovative character of this trial, a non-objection letter (NOL) was required form Health Canada prior to final approval of the trial by the CHUM IRB. (Health Canada NOL registration number: 249512)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Clinical Trials Registration: www.ClinicalTrials.gov. identifier: NCT04458519

  • This work has not been presented publicly, and this paper has not been submitted for consideration or publication elsewhere.

Data Availability

Data is available on request from the senior author, Dr Desrosiers, at martin-yvon.desrosiers.med@sss.gouv.qc.ca

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 20, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
INTRANASAL APPLICATION OF LACTOCOCCUS LACTIS W 136 BACTERIA EARLY IN SARS-Cov-2 INFECTION MAY HAVE A BENEFICIAL IMMUNOMODULATORY EFFECT: A PROOF-OF-CONCEPT STUDY
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
INTRANASAL APPLICATION OF LACTOCOCCUS LACTIS W 136 BACTERIA EARLY IN SARS-Cov-2 INFECTION MAY HAVE A BENEFICIAL IMMUNOMODULATORY EFFECT: A PROOF-OF-CONCEPT STUDY
Leandra Mfuna Endam, Cécile Tremblay, Ali Filali, Martin Yvon Desrosiers
medRxiv 2021.04.18.21255699; doi: https://doi.org/10.1101/2021.04.18.21255699
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
INTRANASAL APPLICATION OF LACTOCOCCUS LACTIS W 136 BACTERIA EARLY IN SARS-Cov-2 INFECTION MAY HAVE A BENEFICIAL IMMUNOMODULATORY EFFECT: A PROOF-OF-CONCEPT STUDY
Leandra Mfuna Endam, Cécile Tremblay, Ali Filali, Martin Yvon Desrosiers
medRxiv 2021.04.18.21255699; doi: https://doi.org/10.1101/2021.04.18.21255699

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (139)
  • Cardiovascular Medicine (1946)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (699)
  • Epidemiology (11102)
  • Forensic Medicine (8)
  • Gastroenterology (624)
  • Genetic and Genomic Medicine (3168)
  • Geriatric Medicine (308)
  • Health Economics (561)
  • Health Informatics (2042)
  • Health Policy (863)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12720)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2986)
  • Nursing (164)
  • Nutrition (463)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1552)
  • Ophthalmology (477)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (912)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2784)
  • Public and Global Health (5591)
  • Radiology and Imaging (1093)
  • Rehabilitation Medicine and Physical Therapy (634)
  • Respiratory Medicine (759)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)